
‘A disaster for all of us': US scientists describe impact of Trump cuts
Donald Trump's assault on science – but particularly climate science – has led to unprecedented funding cuts and staff layoffs across federally funded agencies and programs, threatening to derail research tackling the most pressing issues facing Americans and humanity more broadly. A generation of scientific talent is also on the brink of being lost, with unprecedented political interference at what were previously evidence-driven agencies jeopardizing the future of US industries and economic growth.
Johnson was among scores of scientists conducting vital research across a range of fields from infectious diseases, robotics, education, computer science and the climate crisis, who responded to a Guardian online callout to share their experiences about the impact of the Trump administration's cuts to science funding.
Many said they had already had funding slashed or programs terminated, while others fear that cuts are inevitable and are beginning to search for alternative work – either overseas or outside science. So far, the cuts have led to a 60% reduction in Johnson's team, and fear is mounting over the future of 30 years of climate data and expertise as communities across the country are battered by increasingly destructive extreme weather events.
'We won't be able to afford to continue providing the free and quality tools and services to make our data stores searchable, viewable, usable, and accessible. We might not even be able to afford to keep all the data … this will mean worse forecasts and less effective search and rescue responses leading to unnecessary and avoidable loss of life,' said Johnson (not her real name).
Trump's One Big Beautiful Bill Act (Obbba) calls for a 56% cut to the current $9bn National Science Foundation (NSF) budget, as well as a 73% reduction in staff and fellowships – with graduate students among the hardest hit.
The NSF is the premier federal investor in basic science and engineering, and more than 1,650 grants have also been terminated, according to Grant Watch, a non-profit tracking federally funded research grants under the Trump administration. At the behest of Trump, the hardest hit are studies aimed at addressing the unequal impact of the climate crisis and other environmental hazards, as well as any projects perceived to have a connection to diversity, equity or inclusion (DEI).
An anthropologist who researches the impact of floods and cyclones on public health and food supplies in Madagascar, which is among the most vulnerable nations in the world to the climate crisis but contributed virtually nothing to the catastrophe, is leaving Johns Hopkins for Oxford University after funding for the remainder of her fellowship was threatened.
'I am devastated to leave family, friends and the grad students I am mentoring in the US, but this seemed like the only way to continue work I've been pursuing for 10+ years. I am working on improving climate mitigation and adaptation in an African country. After Trump was elected, the writing was on the wall. There is no way I can write grant applications that will be acceptable to this government.'
A veteran infectious diseases researcher at Ohio State University was forced to abandon a clinical trial for a new medication to treat hypoxemic respiratory failure in Covid patients after the National Institute of Health (NIH) terminated funding midway through the study.
The decision will save $500,000, but $1.5m had already been spent on the trial which researchers hoped would lead to new treatment options for the million or so people hospitalized with respiratory failure each year as a result of flu, Covid and other infections. The trial would have to be repeated from the start, in order to seek approval from the FDA.
'This is a disaster for all of us. We're all depressed and living on a knife-edge, because we know we could lose the rest of our grants any day. These people really hate us yet all we've done is work hard to make people's health better. A flu pandemic is coming for us, what's happening in cattle is truly scary and all we have is oxygen and hope for people,' said the Ohio scientist.
Between 90 and 95% of their lab work is funded through the NIH. So far, more than 3,500 grants have been terminated or frozen by the NIH. Trump's budget proposes slashing NIH funding by more than 40%.
The majority of scientists who got in touch described feeling anxious and despondent – about their own work if the cuts continue, but also about what seems an inevitable loss of talent and knowledge which could upend the US position as a global leader in scientific endeavors and ricochet for years to come.
The brain drain is real. The Australian Academy of Science is leading the country's efforts to proactively recruit top US-based scientists, creating a new global talent program that includes research funding, access to Australian research infrastructure, fast-track visas and a relocation package. At least 75 scientists applied in the first three months of the program, the AAS told the Guardian.
The Trump administration has accused universities, without evidence, of promoting leftwing radical thinking and research, but federal funds train scientists who go on to work for the oil and gas, mining, chemical, big tech and other industries.
Several respondents said the private sector was also starting to feel the knock-on effect of Trump's cuts and tariffs. Wessel van den Bergh, a materials scientist with a PhD, was working on battery storage technology for a Chinese-owned renewable energy company in Massachusetts. He was laid off in early June amid Trump's tariff chaos and attacks on science and renewables, and is struggling to find work.
'When I started my PhD program, America was at the leading edge of batteries/energy storage but this is no longer true due to tariffs, funding cuts, and aggression towards green alternatives. Rather, the US has ceded its hard-earned expertise to other countries such as Korea, Japan and China,' Van den Bergh said.
Trump supports the expansion of fossil fuels and has received millions of dollars in campaign donations from the oil, gas and coal industry, while his budget legislation terminated incentives for solar and wind energy.
'It's crushing, I don't see a clear path ahead any more. I no longer feel this country values science. It's genuinely heartbreaking to build your vocation to something that could genuinely benefit the world for it to be quashed for imagined political victories … especially at a time where these kinds of technologies are the only way out of the climate crisis,' said Van den Bergh.
Separately, the Nuclear Physics Laboratory (NPL) at the University of Illinois got in touch after the Guardian's recent investigation into the chaos at the NSF. For almost 100 years the NPL has been at the forefront of cutting-edge science in drug discovery, cancer treatments, PET scans and other medical diagnoses, and semiconductor testing, with researchers playing a key role in world-renowned institutions like Cern and Los Alamos. It's a major hub for nurturing and training future talent, and at least 50 students have graduated with PhDs in the past 20 years.
It was here that Rosalind Yalow got her PhD in nuclear physics in 1945, and then went on to invent radioimmunoassay – a technique to detect minute amounts of hormones, viruses and drugs in the blood which revolutionized medical testing for conditions such as diabetes. Yalow was awarded the Nobel prize in 1977, only the second woman to win it.
The lab was recently informed that the NSF will reduce funding that supports graduates students from $15m for four years to $1m for one year.
'Our group in nuclear physics at Illinois actually predates the founding of the NSF in 1950, and we have a long history of both producing scientists and accelerator technologies that have had an impact on huge numbers of people,' said Anne M Sickles, professor of nuclear physics.
'If you cut the funding to the people who are doing the work right now, you don't know what they would have innovated in 10 years or 15 years or 32 years like Rosalind Yalow. We don't know what we're losing.'
The NFS declined to comment, while the office of management and budget and NIH did not respond.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
6 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.


The Independent
10 hours ago
- The Independent
‘Fantastic Four: First Steps' scores Marvel's first $100 million box office opening of 2025
Marvel's first family has finally found box office gold. 'The Fantastic Four: First Steps,' the first film about the superheroes made under the guidance of Kevin Feige and the Walt Disney Co., earned $118 million in its first weekend in 4,125 North American theaters, according to studio estimates Sunday. That makes it the fourth biggest opening of the year, behind 'A Minecraft Movie,' 'Lilo & Stitch' and 'Superman,' and the biggest Marvel opening since 'Deadpool & Wolverine' grossed $211 million out of the gate last summer. Internationally, 'Fantastic Four' made $100 million from 52 territories, adding up to a $218 million worldwide debut. The numbers were within the range the studio was expecting. The film arrived in the wake of another big superhero reboot, James Gunn's 'Superman,' which opened three weekends ago and has already crossed $500 million globally. That film, from the other main player in comic book films, DC Studios, took second place with $24.9 million domestically. 'First Steps' is the latest attempt at bringing the superhuman family to the big screen, following lackluster performances for other versions. The film, based on the original Marvel comics, is set during the 1960s in a retro-futuristic world led by the Fantastic Four, a family of astronauts-turned-superhuman from exposure to cosmic rays during a space mission. The family is made up of Reed Richards (Pedro Pascal), who can stretch his body to incredible lengths; Sue Storm (Vanessa Kirby), who can render herself invisible; Johnny Storm (Joseph Quinn), who transforms into a fiery human torch; and Ben Grimm (Ebon Moss-Bachrach), who possesses tremendous superhuman strength with his stone-like flesh. The movie takes place four years after the family gained powers, during which Reed's inventions have transformed technology, and Sue's diplomacy has led to global peace. Both audiences and critics responded positively to the film, which currently has an 88% on Rotten Tomatoes and promising exit poll responses from opening weekend ticket buyers. An estimated 46% of audiences chose to see it on premium screens, including IMAX and other large formats. The once towering Marvel is working to rebuild audience enthusiasm for its films and characters. Its two previous offerings this year did not reach the cosmic box office heights of 'Deadpool & Wolverine," which made over $1.3 billion, or those of the 'Avengers'-era. But critically, the films have been on an upswing since the poorly reviewed 'Captain America: Brave New World,' which ultimately grossed $415 million worldwide. ' Thunderbolts," which jumpstarted the summer movie season, was better received critically but financially is capping out at just over $382 million globally. Like Deadpool and Wolverine, the Fantastic Four characters had been under the banner of 20th Century Fox for years. The studio produced two critically loathed, but decently profitable attempts in the mid-2000s with future Captain America Chris Evans as the Human Torch. In 2015, it tried again (unsuccessfully) with Michael B. Jordan and Miles Teller. They got another chance after Disney's $71 billion acquisition of Fox's entertainment assets in 2019. Top 10 movies by domestic box office With final domestic figures being released Monday, this list factors in the estimated ticket sales for Friday through Sunday at U.S. and Canadian theaters, according to Comscore: 1. 'The Fantastic Four: First Steps,' $118 million. 2. 'Superman,' $24.9 million. 3. 'Jurassic World Rebirth,' $13 million. 4. 'F1: The Movie,' $6.2 million. 5. 'Smurfs,' $5.4 million. 6. 'I Know What You Did Last Summer,' $5.1 million. 7. 'How to Train Your Dragon,' $2.8 million. 8. 'Eddington,' $1.7 million. 9. 'Saiyaara,' $1.3 million. 10. 'Oh, Hi!,' $1.1 million.


The Independent
10 hours ago
- The Independent
This fuzzy animal friend may be the key to treating schizophrenia
Llamas – likely without red pajamas – may hold the key to treating schizophrenia. The serious brain disorder causes people to interpret reality abnormally, and affects approximately 3.7 million U.S. adults between the ages of 18 to 65 years old, according to the nonprofit RTI International. But the domesticated South American woolly animal might be be able to help. French researchers said this week that they had used llama antibodies, or proteins that help to protect the immune system, to design a tiny fragment of an antibody known as a 'nanobody' that will trigger a neurotransmitter in the brain involved in regulating neural activity. Neurotransmitters are chemical molecules that carry messages or signals from one nerve cell to the next target cell, according to the Cleveland Clinic. No llamas were harmed in the study and researchers can identify nanobodies in a petri dish. In the past, llama antibodies have also proven effective in fighting Covid and other 'SARS-like' viruses. When scientists at the Institute of Functional Genomics injected the molecule into the veins or the muscles, it was able to break the blood-brain barrier and effectively reach brain receptors. The barrier is a a tightly locked layer of cells that defend your brain from harmful substances. Studying the impact of the nanobodies in two tests using mice, the researchers found that they corrected cognitive deficits that were observed. There was an improvement of cognitive function with just one shot, and a prolonged effect over one week. Clinical studies are now required to show that their findings could be a new avenue of treatment for schizophrenia. "In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia," molecular biologist Jean-Philippe Pin told Newsweek.. He was a co-author of the research which was published in the journal Nature. Pin said that medications currently given to schizophrenia patients "treat the symptoms well, but less the cognitive deficits." The cause of the chronic condition remains unknown, but the World Health Organization says it is thought that an interaction between genes and a range of environmental factors may be the reason. The exact prevalence of schizophrenia is difficult to measure. Some have tied cases in Canada to cannabis use. Although schizophrenia can occur at any age, people are typically diagnosed between the ages of 16 and 30. Symptoms vary from person to person. There is no cure, but it can be treated through antipsychotic medications, talk therapy, and self-management strategies, the National Alliance on Mental Illness says. The study's authors hope to add this strategy to the list. 'This research confirms the potential of nanobodies as a new therapeutic strategy for acting on the brain, with their use eventually being broadened to include the treatment of other neurological illnesses,' the institute said in a statement.